Moon Chang Mo, Hong Sung Noh
Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Clin Endosc. 2021 Mar;54(2):149-151. doi: 10.5946/ce.2021.068. Epub 2021 Mar 26.
With advancing analytical methods for gut microbes, many studies have been conducted, revealing that gut microbes cause various diseases, including gastrointestinal and non-gastrointestinal diseases. Accordingly, studies have been actively conducted to analyze the effects on the prevention and treatment of these diseases through changes in intestinal microbes and control of dysbiosis. Fecal microbiota transplantation (FMT) is an effort and is currently being applied to Clostridioides difficile treatment in Korea. Many studies have demonstrated the application of FMT in inflammatory bowel disease, irritable bowel syndrome, non-alcoholic fatty liver disease, metabolic syndrome, obesity, and diabetes. With further studies and accumulation of evidence, FMT could help treat presently untreatable diseases in clinical practice.
随着肠道微生物分析方法的不断进步,人们开展了许多研究,结果显示肠道微生物会引发多种疾病,包括胃肠道疾病和非胃肠道疾病。因此,人们积极开展研究,以分析通过改变肠道微生物和控制肠道菌群失调对这些疾病预防和治疗的影响。粪便微生物群移植(FMT)就是这样一种尝试,目前在韩国正应用于艰难梭菌感染的治疗。许多研究已经证明了FMT在炎症性肠病、肠易激综合征、非酒精性脂肪性肝病、代谢综合征、肥胖症和糖尿病中的应用。随着进一步的研究和证据的积累,FMT有望在临床实践中帮助治疗目前无法治愈的疾病。